HLB Reapply for Liver Cancer Drug Approval from FDA
HLB logo. On 16 May this year, the FDA issued a Complete Response Letter (CRL) requesting...
FDA
Popular medicine to treat menopause-related hot flashes can lead to serious liver injury, FDA warns – Healthcare News
The U.S. Food and Drug Administration (FDA) on Friday issued a warning that Veozah (fezolinetant), a medicine used to treat...
Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas
A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full...
FDA Approves Gilead’s Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal – Gilead Sciences (NASDAQ:GILD)
On Wednesday, the FDA granted accelerated approval for Gilead Sciences, Inc.’s GILD Livdelzi (seladelpar) for primary biliary cholangitis (PBC) in combination with...
HLB Fails to Receive US FDA Approval for Rivoceranib Liver Cancer Treatment
The logo of HLB HLB has failed to secure approval from the U.S. Food and Drug...
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer
SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted...
